Skip to main content

Advertisement

Log in

Psoriatic arthritis: Pharmacoeconomic considerations

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

Tumor necrosis factor (TNF) antagonists provide a clinically and economically efficient treatment option for psoriatic arthritis (PsA). PsA is a chronic inflammatory disease affecting the musculoskeletal system that, if untreated, can be disabling due to the progressive joint damage and the considerable impact on functional status and health-related quality of life. Therapies for PsA have been disappointing until recently. Traditional disease-modifying drugs are used to control symptoms, but there is no evidence that they slow the progression of the damage in peripheral joints. The introduction of the TNF-α-blocking agents has revolutionized the therapeutic management of PsA. These drugs lessen symptoms and signs of inflammation, enhance quality of life and functional capacity, and hinder the evolution of structural joint damage. TNF-α blockers are very expensive and not easily available to all patients, either depending on a national system or private insurance. Nevertheless, recent pharmacoeconomic studies have demonstrated that TNF-α blockers are cost-effective treatment options for the musculoskeletal and cutaneous manifestations of psoriatic disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Mooney GH, Drummond MF: Essentials of health economics: Part I. What is economics. Br Med J (Clin Res Ed) 1982, 285:949–950.

    Article  CAS  Google Scholar 

  2. Drummond MF, Sculpher MJ, Torrance GW, et al.: Methods for the Economic Evaluation of Health Care Programmes, edn 3. Oxford, United Kingdom: Oxford University Press; 2005.

    Google Scholar 

  3. National Center of Health Statistics: 1996. Healthy people review. Hyattsville, MD: Public Health Service; 1995–1996.

    Google Scholar 

  4. Murray CJ, Lopez AD: Global mortality, disability, and contribution of risk factors: Global Burden of Disease Study. Lancet 1997, 349:1436–1442.

    Article  PubMed  CAS  Google Scholar 

  5. McHugh NJ, Balachrishnan C, Jones SM: Progression of peripheral joint disease in psoriatic arthritis: a 5-yr prospective study. Rheumatology (Oxford) 2003, 42:778–783.

    Article  CAS  Google Scholar 

  6. Gladman DD, Stafford-Brady F, Chang CH, et al.: Longitudinal study of clinical and radiological progression in psoriatic arthritis. J Rheumatol 1990, 17:809–812.

    PubMed  CAS  Google Scholar 

  7. Torre-Alonso JC, Rodriguez-Perez A, Arribas Castrillo JM, et al.: Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. Br J Rheumatol 1991, 30:245–250.

    Article  PubMed  CAS  Google Scholar 

  8. Kane D, Stafford L, Bresnihan B, FitzGerald O: A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford) 2003, 42:1460–1468.

    Article  CAS  Google Scholar 

  9. Palazzi C, D’Agostino L, D’Amico E, et al.: Asymptomatic erosive peripheral psoriatic arthritis: a frequent finding in Italian patients. Rheumatology (Oxford) 2003, 42:909–911.

    Article  CAS  Google Scholar 

  10. Scarpa R, Cuocolo A, Peluso R, et al.: Early psoriatic arthritis: the clinical spectrum. J Rheumatol 2008, 35:137–141.

    PubMed  Google Scholar 

  11. Lindqvist UR, Alenius GM, Husmark T, et al.: The Swedish early psoriatic arthritis register—2-year follow-up: a comparison with early rheumatoid arthritis. J Rheumatol 2008, 35:668–673.

    PubMed  Google Scholar 

  12. Husted JA, Gladman DD, Farewell VT, et al.: Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997, 24:511–517.

    PubMed  CAS  Google Scholar 

  13. Gladman DD: Disability and quality of life considerations. Psoriatic arthritis. In Psoriatic and Psoriatic Arthritis: An Integral Approach. Edited by Gordon GB, Ruderman E. Heidelberg, Germany: Springer-Verlag; 2005:118–123.

    Google Scholar 

  14. Drummond MF, O’Brien B, Stoddard GL, Torrance GW: Method for the Economic Evaluation in Health Care Programmes, edn 2. Oxford, United Kingdom: Oxford University Press; 1997.

    Google Scholar 

  15. Bansback NJ, Ara R, Barkham N, et al.: Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. Rheumatology (Oxford) 2006, 45:1029–1038.

    Article  CAS  Google Scholar 

  16. Eandi M, Salvarani C: Pharmacoeconomic analysis of biological drugs for the treatment of psoriatic arthritis [in Italian]. Farmacoeconomia e Percorsi Terapeutici 2006, 7:171–186.

    Google Scholar 

  17. Woolacott N, Bravo Vergel Y, Hawkins N, et al.: Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. Health Technol Assess 2006, 10:1–239.

    PubMed  CAS  Google Scholar 

  18. Kavanaugh A, Antoni C, Mease P, et al.: Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. J Rheumatol 2006, 33:2254–2259.

    PubMed  CAS  Google Scholar 

  19. Bravo Vergel Y, Hawkins NS, Claxton K, et al.: The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. Rheumatology 2007, 46:1729–1735.

    Article  PubMed  CAS  Google Scholar 

  20. Olivieri I, de Portu S, Salvarani C, et al.: The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. Rheumatology 2008, 47:1664–1670.

    Article  PubMed  CAS  Google Scholar 

  21. Sizto S, Bansback N, Feldman SR, et al.: Economic evaluation of systemic therapies for moderate to severe psoriasis. Br J Dermatol 2009, 160:1264–1272.

    Article  PubMed  CAS  Google Scholar 

  22. Sokoll KB, Helliwell PS: Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. J Rheumatol 2001, 28:1842–1846.

    PubMed  CAS  Google Scholar 

  23. Gladman DD: Psoriatic arthritis. In Kelley’s Textbook of Rheumatology, edn 7. Edited by Harris ED Jr, Budd RC, Firestein GS, et al.: Philadelphia: Elsevier Saunders; 2005:1155–1164.

    Google Scholar 

  24. Queiro R, Torre JC, Belzunegui J, et al.: Clinical features and predictive factors in psoriatic arthritis-related uveitis. Semin Arthritis Rheum 2002, 31:264–270.

    Article  PubMed  Google Scholar 

  25. Scarpa R, Manguso F, D’Arienzo A, et al.: Microscopic inflammatory changes in colon of patients with both active psoriasis and psoriatic arthritis without bowel symptoms. J Rheumatol 2000, 27:1241–1246.

    PubMed  CAS  Google Scholar 

  26. Mallbris L, Ritchlin CT, Ståle M: Metabolic disorders in patients with psoriasis and psoriatic arthritis. Curr Rheumatol Rep 2006, 8:355–363.

    Article  PubMed  CAS  Google Scholar 

  27. Neimann AL, Shin DB, Wang X, et al.: Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006, 55:829–835.

    Article  PubMed  Google Scholar 

  28. Tam LS, Tomlinson B, Chu TT, et al.: Cardiovascular risk profile of patients with psoriatic arthritis compared to controls—the role of inflammation. Rheumatology (Oxford) 2008, 47:718–723.

    Article  Google Scholar 

  29. Scarpa R, Ayala F, Caporaso N, Olivieri I: Psoriasis, psoriatic arthritis, or psoriatic disease? J Rheumatol 2006, 33:210–212.

    PubMed  Google Scholar 

  30. Ritchlin C: Psoriatic disease—from skin to bone. Nat Clin Pract Rheumatol 2007, 3:698–706.

    Article  PubMed  CAS  Google Scholar 

  31. Ritchlin C: From skin to bone: translational perspectives on psoriatic disease. J Rheumatol 2008, 35:1434–1437.

    PubMed  Google Scholar 

  32. Dougados M, van der Linden S, Juhlin R, et al.: The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991, 34:1218–1227.

    Article  PubMed  CAS  Google Scholar 

  33. Olivieri I, van Tubergen A, Salvarani C, van der Linden S: Seronegative spondyloarthritides. Best Pract Res Clin Rheumatol 2002, 16:723–739.

    Article  PubMed  Google Scholar 

  34. Wong K, Gladman DD, Husted J, et al.: Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997, 40:1868–1872.

    Article  PubMed  CAS  Google Scholar 

  35. Gladman DD, Farewell VT, Wong K, Husted J: Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death. Arthritis Rheum 1998, 41:1103–1110.

    Article  PubMed  CAS  Google Scholar 

  36. Mease PJ, Kivitz AJ, Burch FX, et al.: Etanercept treatment of psoriatic arthritis. Safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264–2272.

    Article  PubMed  CAS  Google Scholar 

  37. Kavanaugh A, Antoni C, Gladman DD, et al.: The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. Ann Rheum Dis 2006, 65:1038–1043.

    Article  PubMed  CAS  Google Scholar 

  38. Mease P, Gladman DD, Ritchlin CT, et al.: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:3279–3289.

    Article  PubMed  CAS  Google Scholar 

  39. Zochling J, van der Heijde D, Dougados M, Braun J: Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006, 65:423–432.

    Article  PubMed  CAS  Google Scholar 

  40. Ritchlin CT, Kavanaugh A, Gladman DD, et al.: Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2008 Oct 24 (Epub ahead of print).

  41. Olivieri I, D’Angelo S, Palazzi C, Padula A: Treatment strategies for early psoriatic arthritis. Expert Opin Pharmacother 2009, 10:271–282.

    Article  PubMed  CAS  Google Scholar 

  42. Javitz HS, Ward MM, Farber E, et al.: The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002, 46:850–860.

    Article  PubMed  Google Scholar 

  43. Huscher D, Merkesdal S, Thiele K, et al.: Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann Rheum Dis 2006, 65:1175–1183.

    Article  PubMed  CAS  Google Scholar 

  44. Kraning KK, Odland GF: Psoriasis. J Invest Dermatol 1979, 73:402–413.

    Article  Google Scholar 

  45. Krueger GG, Bergstresser PR, Lowe NJ, et al.: Psoriasis. J Am Acad Dermatol 1984, 11:937–947.

    Article  PubMed  CAS  Google Scholar 

  46. Ackermann C, Kavanaugh A: Economic burden of psoriatic arthritis. Pharmacoeconomics 2008, 26:121–129.

    Article  PubMed  Google Scholar 

  47. Kavanaugh A: Health economics: implications for novel antirheumatic therapies. Ann Rheum Dis 2005, 64:iv65–69.

    Article  PubMed  Google Scholar 

  48. Kavanaugh A: Pharmacoeconomic considerations in the treatment of psoriatic arthritis. Rheumatology (Oxford) 2006, 45:790–791.

    Article  CAS  Google Scholar 

  49. Messori A, Santarlasci B, Trippoli S, Vaiani M: Drug economic equivalent and clinical benefit: state of the art on methodology and application of a pharmacoeconomic algorithm. Pharmacoeconomics—Italian Research Articles 2003, 5:53–67.

    Google Scholar 

  50. Kimball AB, Jackson JM, Sobell JM, et al.: Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial. J Drugs Dermatol 2007, 6:299–306.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Ignazio Olivieri.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Olivieri, I., Mantovani, L.G., D’Angelo, S. et al. Psoriatic arthritis: Pharmacoeconomic considerations. Curr Rheumatol Rep 11, 263–269 (2009). https://doi.org/10.1007/s11926-009-0037-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-009-0037-x

Keywords

Navigation